Nocion Therapeutics
A biopharmaceutical company developing charged sodium channel blockers (CSCBs) that selectively affect actively firing nociceptors for the treatment of serious conditions involving cough, itch, and pain.
Nocion is developing first and potentially best in class, small molecule, permanently charged sodium channel blockers (CSCBs), called nocions, that selectively silence activated nociceptors.
In March 2024, Nocion announced that it raised $62 million in Series B funding. Proceeds from the financing will be used to evaluate the lead program, Taplucanium Dry Powder for Inhalation, in a Phase IIb study in Chronic Cough patients.
Latest Nocion Therapeutics News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze